Core Viewpoint - WuXi Biologics reported a 16% year-on-year increase in sales for the first half of the year, with adjusted net profit growing by 12%, aligning with market expectations [1] Financial Performance - The management raised the full-year revenue growth guidance from 12%-15% to 14%-16%, anticipating accelerated growth in unfulfilled orders to support long-term growth [1] - The revenue forecast for 2025 to 2027 has been increased by 2% to 9%, while net profit forecasts for 2026 to 2027 have been raised by 6% to 12%, reflecting strong mid-term performance and robust order growth [1] Strategic Insights - Beyond development and production, potential royalties and milestone payments are expected to be key drivers of WuXi Biologics' long-term growth [1] - The target price has been adjusted from HKD 28.8 to HKD 34.8, maintaining an "outperform" rating [1]

Core Viewpoint - The company has raised its profit forecasts for 2025/2026 due to smooth project progress and improved operational efficiency, maintaining an outperform rating in the industry [1] Financial Performance - The company reported 1H25 revenue of 9.95 billion, a year-on-year increase of 16.1%, with a continuous operating business revenue growth of 20.2% [2] - Gross margin reached 42.7%, up 3.6 percentage points year-on-year, while adjusted EBITDA was 4.31 billion, reflecting a 20.6% increase [2] - Adjusted net profit for 1H25 was 2.84 billion, a year-on-year increase of 11.6%, with a corresponding profit margin of 28.5% [2] Business Model and Growth - The CRDMO business model is fully operational, with over 50 molecular projects enabled, and potential milestone payments reaching 9 billion [3] - Revenue from preclinical stage projects was 4.15 billion, up 35.2% year-on-year, driven by research services and preclinical development project conversions [3] - Revenue from clinical phase III and commercialization reached 4.29 billion, a 24.9% increase, supported by the advancement of early projects and ongoing commercialization [3] Project and Order Status - The company signed 86 new projects in 1H25, with over 70% being complex molecules, showcasing its technical capabilities [4] - The company secured 9 new molecular projects, including 2 clinical phase III projects, primarily from the U.S. [4] - The total unfulfilled orders reached 20.3 billion, with approximately 4.2 billion in orders expected to be completed within three years [4] Capacity Expansion - Capital expenditure for 1H25 was approximately 1.9 billion, with an expected total of 5.3 billion for the year [5] - In Singapore, the modular biopharmaceutical production facility has commenced construction, while the modular bulk production facility is in the design phase [5] - In Ireland, the MFG6.2 facility has completed its first engineering batch and PPQ production, and MFG7 has completed its second 12kL scale PPQ production [5]

中金发布研报称，由于药明生物(02269)项目推进顺利以及经营效率提升，上调2025/2026归母净利润预 测5.5%/1.6%至42.1/47.1亿元，上调2025/2026经调整利润预测2.5%/4.1%至51.1/55.8亿元。维持跑赢行业 评级，当前股价对应2025/2026年经调整P/E为21.7x/19.6x。由于医药板块近期估值中枢上移，该行上调 目标价10.8%至36港元，对应2025/2026年经调整P/E为26.3x/23.7x，较当前股价有20.9%上行空间。 中金主要观点如下： 1H25业绩超过该行预期 公司公布1H25业绩：收入99.5亿元，同比+16.1%，持续经营业务收入+20.2%;毛利率42.7%，同比 +3.6ppt;经调整EBITDA43.1亿元，同比+20.6%，对应利润率43.3%;经调整纯利28.4亿元，同比+11.6%， 对应利润率28.5%。超过该行预期，主要因项目推进顺利、商业化项目爬坡、以及经营效率提升。公司 上调2025年收入增速预期至14%-16%，同时指引盈利水平稳步提升以及自由现金流显著增长。 CRDMO商业模式全面发力 1H25，1)R：截至1H2 ...

花旗发表研报指，将药明生物列为委托开发制造商(CDMO)领域首选标的之一，考虑收入增长加快及盈 利能力改善，目标价由35港元上调至40港元，予"买入"评级。另外，该行将2025至27年各年收入预测分 别上调2%、2%及1%，净利润预测分别上调15%、10%及11%。 ...

Investment Rating - The report indicates a positive outlook for the Chinese equity market, particularly for small and mid-cap indices, suggesting a favorable investment environment [2][11][8]. Core Insights - Retail investor flows are significantly driving the recent market uptrend, with substantial dry powder still available on the sidelines for further investment [2][4]. - The Shanghai Composite Index (SHCOMP) reached a new 10-year high of 3766, with the consumption sector leading the gains, particularly in liquor and retail expansion [2][3]. - The report highlights strong earnings from companies in the "New Retail" sector, exemplified by PopMart's 12.5% increase post-earnings [3][24]. - There is a notable resilience in the Chinese A-share market, which has attracted significant inflows, contrasting with the sell-off in US tech stocks [4][5]. - The report emphasizes the long-term upside potential in small and mid-cap indices, particularly the CSI1000, due to favorable market conditions and investor sentiment [8][11]. Summary by Sections Retail Investor Dynamics - Retail ownership in indices like CSI1000 and CSI500 is high at 61% and 51% respectively, compared to foreign ownership of only 2.5% and 1.4% [18]. - The CSI1000 index has the highest exposure to margin trading at $62 billion, representing 3.5% of its market cap, indicating a sensitivity to market performance [18]. Market Performance and Trends - Approximately 10% of SHCOMP and 8% of SZCOMP constituents have reached new 52-week highs, indicating a broadening rally [11]. - About 90% of stocks in SHCOMP/SZCOMP are trading above their 50-day moving average, suggesting strong momentum [11]. - The report notes a shift towards higher quality investments, with increased turnover in mid-cap stocks (CSI500) and decreased turnover in micro-cap stocks (CSI2000) [12]. Financial Insights - Goldman Sachs estimates that Chinese households hold approximately 55 trillion yuan in excess deposits, with 22% of household financial assets allocated to mutual funds and equities, indicating potential inflows exceeding 10 trillion yuan into the market [12][13]. - The report outlines the favorable earnings growth projections for various indices, with CSI1000 expected to have a 2025 EPS growth of 54% [18]. Sector Exposure - The CSI1000 index has only about 10% weight in traditional sectors like Financials and Real Estate, while it has a higher exposure to technology and healthcare, aligning with strategic policy directions [18].

Core Insights - WuXi Biologics reported a 16.1% year-on-year revenue growth to 9.95 billion yuan for the first half of 2025, driven by the successful execution of its "Follow and Win Molecule" strategy and expansion of service offerings in the biopharmaceutical industry [1] - The company's IFRS net profit increased by 54.8% to 2.76 billion yuan, with profit attributable to shareholders rising by 56.0% to 2.34 billion yuan, primarily due to gross profit growth and returns from investments and asset optimization [1] - WuXi Biologics added 86 comprehensive development projects in the first half of 2025, with over 70% of new projects involving bispecific/multispecific antibodies and ADCs [1] Financial Performance - The company supported 67 clinical phase III projects and 24 commercial production projects as of June 30, 2025, with a 24.9% year-on-year increase in revenue from clinical phase III and commercial production, indicating a maturation of early projects and ongoing growth of existing commercial projects [2] - WuXi Biologics has a total unfulfilled order backlog of 20.34 billion USD, with unfulfilled service orders and potential milestone payment orders amounting to 11.35 billion USD and 9 billion USD, respectively [2] - The unfulfilled orders over the next three years increased from 3.65 billion USD in December 2024 to 4.21 billion USD, reinforcing expectations for near-term revenue growth [2] Future Outlook - Based on current performance, WuXi Biologics has raised its full-year revenue guidance for 2025 [3]

Core Viewpoint - The CRO (Contract Research Organization) industry is expected to enter a new development phase as adjustments are largely completed, with several broker reports indicating a recovery in the domestic pharmaceutical investment landscape in the second half of 2025 [1][4]. Company Summary - WuXi Biologics reported a revenue of 9.95 billion yuan for the first half of 2025, representing a year-on-year growth of 16.1%, and a net profit of 2.76 billion yuan, up 54.8% year-on-year [1][2]. - As of June 30, 2025, the total value of uncompleted orders reached 20.34 billion USD, with a three-year increase of 4.21 billion USD, reinforcing revenue growth expectations [2][3]. - The CEO of WuXi Biologics highlighted a robust performance with 86 new comprehensive projects signed, marking a record high for the same period [2]. - The company’s revenue from preclinical services grew by 35.2% year-on-year, benefiting from the transition of R&D service projects to the development phase [2][3]. - WuXi Biologics supported 67 clinical phase III projects and 24 commercial production projects, with revenues from these areas increasing by 24.9% year-on-year [2]. Industry Summary - Multiple broker reports suggest that the CRO industry has completed its adjustments and is poised for a new growth phase, with a recovery in global pharmaceutical investment expected by the end of 2023 [4]. - The domestic investment landscape is anticipated to recover in the second half of 2025, driven by a combination of internal and external demand, which may lead to continuous valuation recovery in the industry [4]. - The CRO industry returned to positive growth in the first quarter of this year, with expectations for this trend to continue throughout the year [4]. - Certain sub-sectors, such as peptides and ADCs, are benefiting from high demand, while the CDMO (Contract Development and Manufacturing Organization) sector is expected to maintain rapid growth [4].

Financial Data and Key Metrics Changes - Revenue reached nearly RMB 10 billion, representing a 16.1% increase year-over-year [28] - Adjusted EBITDA increased by 20.6% to RMB 4.3 billion, with an adjusted EBITDA margin of 43.3% [35][36] - Adjusted net profit exceeded RMB 2.8 billion, reflecting an 11.6% year-over-year increase [36] - Gross profit margin improved from 39.1% to 42.7%, with adjusted gross profit margin at 45.6% [7][40] Business Line Data and Key Metrics Changes - Research and Development (R&D) revenue grew over 35% year-over-year, driven by a strong pipeline of projects [30] - Late-phase and commercial manufacturing revenue grew close to 25%, representing over 43% of the total portfolio [30] - Early-phase revenue saw a decline due to timing issues with large-scale clinical manufacturing projects transitioning from phase two to phase three [30][31] Market Data and Key Metrics Changes - North America accounted for nearly 60% of revenue, with a growth rate of 20% [23] - Europe contributed close to 20% of revenue, showing modest growth as the company shifts focus from CMO projects to early-phase programs [24] - China represented 13% of revenue, experiencing a single-digit decline primarily due to out-licensing of programs to global partners [25] - Asia, particularly Japan, Korea, and Singapore, showed significant growth, now accounting for nearly 7% of revenue with more than double the growth rate [26] Company Strategy and Development Direction - The company emphasizes a unique CRDMO model, focusing on both service-based and IP-driven revenue streams [50][57] - The strategy includes expanding capacity globally, with significant investments in facilities in the US, Ireland, and Singapore [47][79] - The company aims to leverage its strong portfolio in ADCs and bispecifics, which now account for over 40% of its project portfolio [22] Management's Comments on Operating Environment and Future Outlook - Management noted that the company has absorbed post-COVID industry adjustments and is positioned for accelerated growth [28] - The backlog has shown significant growth, with milestone backlog increasing from RMB 7 billion to RMB 9 billion and service backlog from RMB 10 billion to RMB 11.3 billion [16][17] - The company expects to continue benefiting from global biotech trends, including M&A activities and out-licensing of Chinese assets to global partners [63][64] Other Important Information - The company achieved a 100% success rate in regulatory inspections, hosting 44 inspections [6] - Employee retention rate remains high at 98.8%, with no increase in total employee numbers over the past 18 months [42] - The company has a strong cash position with RMB 12.5 billion on hand and a conservative debt level of RMB 2.7 billion [43][47] Q&A Session Summary Question: What are the key drivers for revenue growth in the upcoming quarters? - Management highlighted the successful execution of the follow and win molecule strategies, with a strong pipeline of late-phase projects expected to ramp up [29] Question: How does the company plan to address the decline in early-phase revenue? - The decline is attributed to timing issues with large-scale projects transitioning to manufacturing, which is expected to be replenished by new projects in the pre-IND space [30][31] Question: What is the company's outlook on the global market trends? - Management expressed confidence in continued growth driven by M&A activities and the out-licensing of Chinese biotech programs to global partners, which typically results in significant revenue amplification [63][64]

Financial Data and Key Metrics Changes - Revenue reached nearly RMB 10 billion, representing a 16.1% increase year-over-year [27] - Adjusted EBITDA increased by 20.6% to RMB 4.3 billion, with an adjusted EBITDA margin of 43.3% [34] - Adjusted net profit exceeded RMB 2.8 billion, an 11.6% increase year-over-year [35] - Gross profit margin improved from 39.1% to 42.7%, with a gross profit increase of RMB 900 million [32][38] Business Line Data and Key Metrics Changes - Early phase R&D revenue grew over 35%, while late phase manufacturing revenue increased by nearly 25% [28][29] - The company added a record 86 new projects in the first half of the year, continuing strong momentum from the previous year [4][28] - The backlog grew significantly, with milestone backlog increasing from RMB 7 billion to RMB 9 billion and service backlog from RMB 10 billion to RMB 11.3 billion [16][17] Market Data and Key Metrics Changes - North America accounted for nearly 60% of revenue, with a growth rate of 20% [22] - Europe contributed close to 20% of revenue with modest growth, while China accounted for 13% with a single-digit decline [24] - Asia, particularly Japan, Korea, and Singapore, saw revenue growth exceeding 100% [25] Company Strategy and Development Direction - The company emphasizes its unique CRDMO model, which integrates R&D, development, and manufacturing [50][58] - Focus on expanding capabilities in ADCs and bispecifics, with over 300 projects in the pipeline [19][21] - Plans to enhance global capacity, with significant expansions in the US, Ireland, and Singapore [76][80] Management's Comments on Operating Environment and Future Outlook - Management noted that the company has absorbed post-COVID industry adjustments and is positioned for accelerated growth [27][28] - The company expects to continue benefiting from the increasing number of projects moving through its golden funnel [28] - Management expressed confidence in achieving positive free cash flow for the fourth consecutive year [48] Other Important Information - The company maintained a high employee retention rate of 98.8% and stable employee numbers despite revenue growth [6] - The company has a strong balance sheet with RMB 12.5 billion in cash and a conservative debt level of RMB 2.7 billion [42][47] - The company achieved a 100% success rate in regulatory inspections, reinforcing its quality assurance [6][81] Q&A Session Summary Question: What are the key drivers of revenue growth? - Revenue growth was primarily driven by successful execution of the follow and win the molecule strategies, with late phase and commercial manufacturing revenue growing close to 25% [28][29] Question: How is the company addressing the decline in early phase revenue? - The decline in early phase revenue is attributed to timing issues as several large-scale projects progressed from phase two to phase three, which is expected to be replenished by new projects [29] Question: What is the company's strategy for expanding its market presence? - The company aims to leverage its strong market share in China and capitalize on global licensing trends, expecting revenue to grow significantly as projects are out-licensed to global partners [64][65]

© 2025 WuXi Biologics. All rights reserved. 2 CRDMO Business Model: Accelerating Growth 2025 Interim Results August 2025 Stock Code: 2269.HK Forward-Looking Statements This presentation may contain certain "forward-looking statements" which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently unce ...